|
|
|
|
| LEADER |
01083nam a2200289 a 4500 |
| 001 |
c000039444 |
| 003 |
CARM |
| 005 |
19860725000000.0 |
| 008 |
721018s1972 enka b 001 0 eng |
| 010 |
|
|
|a 72075311 //r862
|
| 019 |
1 |
|
|a 582170
|z 10210500
|5 LACONCORD2021
|
| 020 |
|
|
|a 0080168515
|
| 035 |
|
|
|a (OCoLC)488391
|5 LACONCORD2021
|
| 040 |
|
|
|a LC
|b eng
|c LC
|d LC
|
| 050 |
0 |
0 |
|a QP801.H7
|b L39 1972
|
| 082 |
0 |
4 |
|a 612/.396
|
| 100 |
1 |
|
|a Lefebvre, P. J.
|q (Pierre J.),
|d 1934-
|
| 245 |
1 |
0 |
|a Glucagon; molecular physiology, clinical and therapeutic implications.
|c Edited by Pierre J. Lefebvre and Roger H. Unger.
|
| 250 |
|
|
|a [1st ed.]
|
| 260 |
|
|
|a Oxford,
|a New York,
|b Pergamon Press
|c [1972]
|
| 300 |
|
|
|a xiii, 370 p.
|b illus.
|c 26 cm.
|
| 504 |
|
|
|a Includes bibliographies.
|
| 650 |
|
0 |
|a Glucagon.
|
| 700 |
1 |
|
|a Unger, Roger H,
|e joint author.
|
| 852 |
8 |
|
|b CARM
|h A2:AD32E0
|i C00037
|p 0000819
|f BK
|
| 999 |
f |
f |
|i 52a95b30-a3a2-5088-b185-b3daee856405
|s 49a58957-d53f-5831-96c9-1ee8610ec6d6
|
| 952 |
f |
f |
|p Can circulate
|a CAVAL
|b CAVAL
|c CAVAL
|d CARM 1 Store
|e C00037
|f A2:AD32E0
|h Other scheme
|i book
|m 0000819
|